Given the refinement of HER2-low interpretation guidelines in breast cancer, we hope that standardized criteria more suitable for the expression characteristics of gynecologic tumors, particularly for HER2-low interpretation, will be established soon. The gene discussed is ERBB2; the disease is female reproductive system neoplasm.